Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6961 to 6975 of 8218 results

  1. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued Reference number: GID-TA11204

    Technology appraisal guidance
    Discontinued

  2. Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]

    In development Reference number: GID-TA10843 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]

    Discontinued Reference number: GID-TA10583

    Technology appraisal guidance
    Discontinued

  4. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued Reference number: GID-TA10861

    Technology appraisal guidance
    Discontinued

  5. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development Reference number: GID-TA11165 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  7. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  8. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  9. Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]

    In development Reference number: GID-TAG499 Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

    Discontinued Reference number: GID-TAG507

    Technology appraisal guidance
    Discontinued

  11. Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

    Discontinued Reference number: GID-TAG511

    Technology appraisal guidance
    Discontinued

  12. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  13. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development Reference number: GID-TA11093 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148]

    In development Reference number: GID-TA11074 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180]

    In development Reference number: GID-TA11146 Expected publication date: TBC

    Technology appraisal guidance
    In development